The value of FDG PET/CT in treatment response assessment, follow-up, and surveillance of lung cancer
S Sheikhbahaei, E Mena… - American Journal of …, 2017 - Am Roentgen Ray Soc
OBJECTIVE. The purpose of this article is to summarize the evidence regarding the role of
FDG PET/CT in treatment response assessment and surveillance of lung cancer and to …
FDG PET/CT in treatment response assessment and surveillance of lung cancer and to …
PET in the management of locally advanced and metastatic NSCLC
W Grootjans, LF de Geus-Oei, EGC Troost… - Nature reviews Clinical …, 2015 - nature.com
Despite considerable improvements in the treatment options for advanced-stage non-small-
cell lung cancer (NSCLC), disease-specific survival remains poor. With the aim of improving …
cell lung cancer (NSCLC), disease-specific survival remains poor. With the aim of improving …
Prediction of Survival by [18F]Fluorodeoxyglucose Positron Emission Tomography in Patients With Locally Advanced Non–Small-Cell Lung Cancer Undergoing …
Purpose In this prospective National Cancer Institute–funded American College of
Radiology Imaging Network/Radiation Therapy Oncology Group cooperative group trial, we …
Radiology Imaging Network/Radiation Therapy Oncology Group cooperative group trial, we …
Use of dual-point fluorodeoxyglucose imaging to enhance sensitivity and specificity
O Schillaci - Seminars in nuclear medicine, 2012 - Elsevier
Positron emission tomography (PET) and positron emission tomography/computed
tomography imaging with fluorodeoxyglucose (FDG) are widely used as a powerful …
tomography imaging with fluorodeoxyglucose (FDG) are widely used as a powerful …
Advanced kinetic modelling strategies: towards adoption in clinical PET imaging
FA Kotasidis, C Tsoumpas, A Rahmim - Clinical and Translational Imaging, 2014 - Springer
Positron emission tomography (PET) is a highly quantitative imaging modality that can probe
a number of functional and biological processes, depending on the radio-labelled tracer …
a number of functional and biological processes, depending on the radio-labelled tracer …
Dual-time-point imaging and delayed-time-point fluorodeoxyglucose-PET/computed tomography imaging in various clinical settings
Fluorodeoxyglucose (FDG)-PET/computed tomography (CT) imaging enables clinicians to
assess cancer biology and perform staging, restaging, and treatment monitoring of cancers …
assess cancer biology and perform staging, restaging, and treatment monitoring of cancers …
Independent prognostic value of whole-body metabolic tumor burden from FDG-PET in non-small cell lung cancer
H Zhang, K Wroblewski, D Appelbaum, Y Pu - International journal of …, 2013 - Springer
Purpose To determine whether whole-body metabolic tumor burden, measured as either
metabolic tumor volume (MTV WB) or total lesion glycolysis (TLG WB), using FDG-PET/CT is …
metabolic tumor volume (MTV WB) or total lesion glycolysis (TLG WB), using FDG-PET/CT is …
Volume-based parameters on FDG PET may predict the proliferative potential of soft-tissue sarcomas
T Kitao, T Shiga, K Hirata, M Sekizawa, T Takei… - Annals of nuclear …, 2019 - Springer
Introduction Soft-tissue sarcomas (STS) are rare types of tumors that have variable levels of
tumor differentiation. F-18 fluorodeoxyglucose positron emission tomography (FDG PET) …
tumor differentiation. F-18 fluorodeoxyglucose positron emission tomography (FDG PET) …
[HTML][HTML] 837 18F-FDG 与18F-FLT PET/CT 在肺结核瘤与恶性肿瘤鉴别诊断中的应用
陈文新， 林美福， 田嘉禾， 杨小丰， 于丽娟， 王雪梅… - 2012 - zglcyxyxzz.org
目的: 探讨18F-FDG 与18F-FLT 显像在诊断与鉴别肺结节尤其是肺结核与恶性肿瘤中的效能.
方法: 肺结节患者163 例, 年龄17~ 92 岁, 其中结核瘤组29 例, 其它良性结节组46 例 …
方法: 肺结节患者163 例, 年龄17~ 92 岁, 其中结核瘤组29 例, 其它良性结节组46 例 …
Prognostic evaluation of percentage variation of metabolic tumor burden calculated by dual‐phase 18FDG PET‐CT imaging in patients with head and neck cancer
R Abgral, G Valette, P Robin, J Rousset… - Head & …, 2016 - Wiley Online Library
Background The purpose of this study was to investigate the prognostic value of percentage
variation of metabolic tumor burden in patients with head and neck squamous cell …
variation of metabolic tumor burden in patients with head and neck squamous cell …